Table 2B.
PD-L1 expression in GEA Foundation Medicine cohort, by EGFR amplification status
All GEA | EGJ | Gastric | GEA EGFR WT | GEA EGFR AMP | |
---|---|---|---|---|---|
| |||||
No. cases with PD-L1 IHC | 632 | 377 | 255 | 591 | 41 |
| |||||
PD-L1 tumor (%) | |||||
High positive | 20 (3) | 12 (3) | 8 (3) | 20 (3) | 0 |
Low positive | 89 (14) | 56 (15) | 33 (13) | 84 (14) | 5 (12) |
Negative | 523 (83) | 309 (82) | 214 (84) | 487 (82) | 36 (88) |
| |||||
PD-L1 TILs (%) | |||||
High positive | 1 (0.2) | 0 | 1 (0.4) | 1 (0.2) | 0 |
Low positive | 110 (17) | 72 (19) | 38 (15) | 105 (18) | 5 (12) |
Negative | 521 (82) | 305 (81) | 216 (85) | 485 (82) | 36 (88) |
| |||||
PD-LI CPS (%) | |||||
Positive (≥1%) | 166 (26) | 106 (28) | 60 (24) | 159 (27) | 7 (17) |
Negative | 466 (74) | 271 (72) | 195 (76) | 432 (73) | 34 (83) |